MARKET

PSNL

PSNL

Personalis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.36
-0.14
-0.72%
Opening 13:18 05/11 EDT
OPEN
18.20
PREV CLOSE
19.50
HIGH
19.63
LOW
18.00
VOLUME
781.05K
TURNOVER
--
52 WEEK HIGH
53.46
52 WEEK LOW
10.02
MARKET CAP
847.38M
P/E (TTM)
-16.1778
1D
5D
1M
3M
1Y
5Y
Morgan Stanley Maintains Overweight on Personalis, Lowers Price Target to $35
Morgan Stanley maintains Personalis (NASDAQ:PSNL) with a Overweight and lowers the price target from $38 to $35.
Benzinga · 4d ago
--Morgan Stanley Adjusts Personalis PT to $35 From $38, Maintains Overweight Rating
MT Newswires · 4d ago
Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2021
 
Benzinga · 5d ago
Weighing in on vaccine patent waivers, Alcon and Ultragenyx upgraded at Citi and more in analyst action
Analysts weigh in on potential of COVID-19 patent waiversYesterday's announcement that the U.S. would support a waiver of IP protections for COVID-19 vaccines led to a slide in vaccine makers.However,
Seekingalpha · 5d ago
NKLA, ZNGA, HIMX and RUN among notable premarket gainers
Stealth BioTherapeutics (MITO) +58% after showcases data for Elamipretide.Luokung Technology Corp. (LKCO) +22% on announcing favorable ruling granting preliminary injunction.Nemaura Medical (NMRD) +23% on 200K sugarBEAT sensors order.American Shared Hospit...
Seekingalpha · 5d ago
Oppenheimer Upgrades Personalis to Outperform, Announces $28 Price Target
Oppenheimer analyst Kevin Degeeter upgrades Personalis (NASDAQ:PSNL) from Perform to Outperform and announces $28 price target.
Benzinga · 5d ago
--Oppenheimer Upgrades Personalis to Outperform From Perform as Pharma Business Sets Up for High Growth, $28 PT
MT Newswires · 5d ago
Personalis (PSNL) Gets a Buy Rating from BTIG
SmarterAnalyst · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PSNL. Analyze the recent business situations of Personalis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PSNL stock price target is 36.00 with a high estimate of 50.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 185
Institutional Holdings: 31.95M
% Owned: 73.01%
Shares Outstanding: 43.77M
TypeInstitutionsShares
Increased
42
5.90M
New
49
2.20M
Decreased
32
2.36M
Sold Out
7
4.59M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.11%
Pharmaceuticals & Medical Research
-0.39%
Key Executives
Chairman/Independent Director
Jonathan MacQuitty
Non-Executive Chairman/Independent Director
Jonathan Macquitty
President/Chief Executive Officer/Director
John West
Chief Financial Officer
Aaron Tachibana
Chief Human Resource Officer/Vice President
Susan Moriconi
Chief Scientific Officer
Richard Chen
Independent Director
A. Blaine Bowman
Independent Director
Alan Colowick
Independent Director
Karin Eastham
Independent Director
Kenneth Ludlum
Independent Director
Woodrow Myers
Independent Director
Paul Ricci
No Data
About PSNL
Personalis, Inc. is a cancer genomics company. The Company is focused on the development of therapies by providing molecular data about each patient’s cancer and immune response. The Company has designed NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. It also report on the entire transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.

Webull offers kinds of Personalis Inc stock information, including NASDAQ:PSNL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSNL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSNL stock methods without spending real money on the virtual paper trading platform.